Genome-Wide Association Study of Peripheral Artery Disease

Supplemental Digital Content is available in the text. Background: Peripheral artery disease (PAD) affects >200 million people worldwide and is associated with high mortality and morbidity. We sought to identify genomic variants associated with PAD overall and in the contexts of diabetes and smoking status. Methods: We identified genetic variants associated with PAD and then meta-analyzed with published summary statistics from the Million Veterans Program and UK Biobank to replicate their findings. Next, we ran stratified genome-wide association analysis in ever smokers, never smokers, individuals with diabetes, and individuals with no history of diabetes and corresponding interaction analyses, to identify variants that modify the risk of PAD by diabetic or smoking status. Results: We identified 5 genome-wide significant (Passociation ≤5×10−8) associations with PAD in 449 548 (Ncases=12 086) individuals of European ancestry near LPA (lipoprotein [a]), CDKN2BAS1 (CDKN2B antisense RNA 1), SH2B3 (SH2B adaptor protein 3) - PTPN11 (protein tyrosine phosphatase non-receptor type 11), HDAC9 (histone deacetylase 9), and CHRNA3 (cholinergic receptor nicotinic alpha 3 subunit) loci (which overlapped previously reported associations). Meta-analysis with variants previously associated with PAD showed that 18 of 19 published variants remained genome-wide significant. In individuals with diabetes, rs116405693 at the CCSER1 (coiled-coil serine rich protein 1) locus was associated with PAD (odds ratio [95% CI], 1.51 [1.32–1.74], Pdiabetes=2.5×10−9, Pinteractionwithdiabetes=5.3×10−7). Furthermore, in smokers, rs12910984 at the CHRNA3 locus was associated with PAD (odds ratio [95% CI], 1.15 [1.11–1.19], Psmokers=9.3×10−10, Pinteractionwithsmoking=3.9×10−5). Conclusions: Our analyses confirm the published genetic associations with PAD and identify novel variants that may influence susceptibility to PAD in the context of diabetes or smoking status.

[1]  Sara M. Willems,et al.  Genetic Predisposition to Coronary Artery Disease in Type 2 Diabetes Mellitus , 2020, Circulation. Genomic and precision medicine.

[2]  V. M. V. Program Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis , 2020 .

[3]  F. Mach,et al.  Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease , 2020, Drugs.

[4]  Patrick R. Alba,et al.  Genome-wide Association Study of Peripheral Artery Disease in the Million Veteran Program , 2019, Nature Medicine.

[5]  P. Hogan,et al.  The Economic Burden of Elevated Blood Glucose Levels in 2017: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes , 2019, Diabetes Care.

[6]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association , 2019, Circulation.

[7]  Anthony J. Payne,et al.  Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps , 2018, Nature Genetics.

[8]  A. Horsch,et al.  Peripheral artery disease , 2018, British Medical Journal.

[9]  P. Deloukas,et al.  Loss of Cardioprotective Effects at the ADAMTS7 Locus as a Result of Gene-Smoking Interactions , 2017, Circulation.

[10]  S. Tsimikas A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. , 2017, Journal of the American College of Cardiology.

[11]  M. McCarthy,et al.  The Genetic Landscape of Renal Complications in Type 1 Diabetes. , 2017, Journal of the American Society of Nephrology : JASN.

[12]  Gonçalo R. Abecasis,et al.  Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. , 2016, Journal of the American College of Cardiology.

[13]  S. Crooke,et al.  Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials , 2016, The Lancet.

[14]  Stephen Burgess,et al.  PhenoScanner: a database of human genotype–phenotype associations , 2016, Bioinform..

[15]  Tom R. Gaunt,et al.  LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis , 2016, bioRxiv.

[16]  I. Kullo,et al.  CLINICAL PRACTICE. Peripheral Artery Disease. , 2016, The New England journal of medicine.

[17]  T. Morizono,et al.  Genome-Wide Association Study of Peripheral Arterial Disease in a Japanese Population , 2015, PloS one.

[18]  J. Danesh,et al.  A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease , 2016 .

[19]  E. Armstrong,et al.  Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes. , 2015, World journal of diabetes.

[20]  I. Kullo,et al.  The genetic basis of peripheral arterial disease: current knowledge, challenges, and future directions. , 2015, Circulation research.

[21]  M. Daly,et al.  An Atlas of Genetic Correlations across Human Diseases and Traits , 2015, Nature Genetics.

[22]  Ross M. Fraser,et al.  Genetic studies of body mass index yield new insights for obesity biology , 2015, Nature.

[23]  M. Daly,et al.  LD Score regression distinguishes confounding from polygenicity in genome-wide association studies , 2014, Nature Genetics.

[24]  C. Chute,et al.  The ATXN2-SH2B3 locus is associated with peripheral arterial disease: an electronic medical record-based genome-wide association study , 2014, Front. Genet..

[25]  Pankaj Sharma,et al.  Shared Genetic Susceptibility to Ischemic Stroke and Coronary Artery Disease: A Genome-Wide Analysis of Common Variants , 2014, Stroke.

[26]  I. Kullo,et al.  An electronic medical record-linked biorepository to identify novel biomarkers for atherosclerotic cardiovascular disease , 2013, Global cardiology science & practice.

[27]  Igor Rudan,et al.  Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis , 2013, The Lancet.

[28]  Tanya M. Teslovich,et al.  Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.

[29]  K. Bailey,et al.  Disease Location Is Associated With Survival in Patients With Peripheral Arterial Disease , 2013, Journal of the American Heart Association.

[30]  Ross M. Fraser,et al.  Sex-stratified Genome-wide Association Studies Including 270,000 Individuals Show Sexual Dimorphism in Genetic Loci for Anthropometric Traits , 2013, PLoS genetics.

[31]  C. Herzog,et al.  Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[32]  Tanya M. Teslovich,et al.  Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes , 2012, Nature Genetics.

[33]  Inês Barroso,et al.  Genome-Wide Association Identifies Nine Common Variants Associated With Fasting Proinsulin Levels and Provides New Insights Into the Pathophysiology of Type 2 Diabetes , 2011, Diabetes.

[34]  R. Collins,et al.  Lipoprotein(a) Genetic Variants Associated With Coronary and Peripheral Vascular Disease but Not With Stroke Risk in the Heart Protection Study , 2011, Circulation. Cardiovascular genetics.

[35]  P. Visscher,et al.  GCTA: a tool for genome-wide complex trait analysis. , 2011, American journal of human genetics.

[36]  Jin Fan,et al.  Leveraging informatics for genetic studies: use of the electronic medical record to enable a genome-wide association study of peripheral arterial disease , 2010, J. Am. Medical Informatics Assoc..

[37]  Reedik Mägi,et al.  GWAMA: software for genome-wide association meta-analysis , 2010, BMC Bioinformatics.

[38]  R. Collins,et al.  Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.

[39]  John P. Rice,et al.  Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[40]  Deepak L. Bhatt,et al.  One-Year Costs in Patients With a History of or at Risk for Atherothrombosis in the United States , 2008, Circulation. Cardiovascular quality and outcomes.

[41]  Daniel F. Gudbjartsson,et al.  A variant associated with nicotine dependence, lung cancer and peripheral arterial disease , 2008, Nature.

[42]  G. Abecasis,et al.  Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies , 2006, Nature Genetics.

[43]  Merlin C. Thomas,et al.  Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). , 2005, Diabetes care.

[44]  M. Prins,et al.  Influence of smoking on incidence and prevalence of peripheral arterial disease. , 2004, Journal of vascular surgery.

[45]  M. Creager,et al.  The relationship of cigarette smoking to peripheral arterial disease. , 2004, Reviews in cardiovascular medicine.

[46]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[47]  R. Holman,et al.  UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. , 2002, Diabetes care.

[48]  Kári Stefánsson,et al.  Protection of privacy by third-party encryption in genetic research in Iceland , 2000, European Journal of Human Genetics.

[49]  B. Miller,et al.  Contribution of genetic and environmental influences to ankle-brachial blood pressure index in the NHLBI Twin Study. National Heart, Lung, and Blood Institute. , 2000, American journal of epidemiology.